Invirsa Inc.
Columbus, US · Founded 2016 · 5 known investors
Invirsa is a clinical-stage biopharmaceutical company developing DNA damage response therapeutics, with lead compound INV-102 in development for ocular conditions including sulfur mustard gas injury and diabetic dry eye disease.
BiotechDigital HealthMedical Devices
Founders & leadership
RW
Rachael WingoExecutive Officer
TW
Tim WillisDirector
RS
Robert ShalwitzExecutive Officer, Director
BG
Bethany GeorgeDirector
MV
Michael VenerableDirector
WE
Wayne EmbreeDirector
FV
Faith VoinovichDirector
Investors · 5
Reported raises · per SEC filings
Form D private placements$2.9MraisedAug 2025 · 14 investors · Pharmaceuticals
Rule 506(b)$1000KraisedNov 2023 · 1 investors · Pharmaceuticals
Rule 506(b)$6MraisedDec 2022 · 8 investors · Pharmaceuticals
Rule 506(b)$40.2KraisedDec 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Invirsa, Inc. Raises $15.2M to Advance INV-102 Clinical Trialsleadsontrees.com · 2025
- Invirsa raises $18M for diabetic dry eye treatment trials - Columbus Business Firstbizjournals.com · 2025
- Invirsa secures $7.7 million in funding to advance ocular candidateglance.eyesoneyecare.com · 2023
- CincyTech leads Invirsa's $7.7M Series B to fuel series of Phase 2 studies - Cincinnati Business Courierbizjournals.com · 2023
- Invirsa Secures $520K in Seed Funding - FinSMEsfinsmes.com · 2017
- Invirsa Completes $7.7M Series B Financingstreetinsider.com